| FDA-approved Drug |
Target |
In vivo Model: Organ I/R Injury |
Reference |
Etanercept (Enbrel®);
sTNFR-IgG1 Fc |
TNF-α |
Human: heart |
Clinical trial ID: NCT01372930, Phase IV.
Location: Xijing Hospital, Xi’an, Shanxi, China |
| Etanercept (Enbrel®) |
TNF-α |
Rat: kidney |
[201] |
| Etanercept (Enbrel®) |
TNF-α |
Dog: heart |
[130] |
| Infliximab (Remicade®) |
TNF-α |
Rat: liver |
[131] |
| Infliximab (Remicade®) |
TNF-α |
Rabbit: spinal cord |
[132] |
| Infliximab (Remicade®) |
TNF-α |
Rat: small bowel |
[133] |
| Infliximab (Remicade®) |
TNF-α |
Swine: heart |
[134,135] |
| Adalimumab (Humira®) |
TNF-α |
None published |
None published |
|